for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-EMA Says Increase In Vaccine Manufacturing Capacity, Supply For COVID-19 Vaccines From Biontech/Pfizer & Moderna

April 23 (Reuters) -

* EMA SAYS INCREASE IN VACCINE MANUFACTURING CAPACITY AND SUPPLY FOR COVID-19 VACCINES FROM BIONTECH/PFIZER AND MODERNA

* EMA - APPROVED AN INCREASE IN BATCH SIZE AND ASSOCIATED PROCESS SCALE UP AT PFIZER’S VACCINE MANUFACTURING SITE IN PUURS, BELGIUM

* EMA SAYS EMA HAS APPROVED AN INCREASE IN BATCH SIZE AND ASSOCIATED PROCESS SCALE UP AT PFIZER’S VACCINE MANUFACTURING SITE IN PUURS, BELGIUM

* EMA SAYS CHMP ALSO RECOMMENDED APPROVAL OF A NEW FILLING LINE AT MODERNA’S FINISHED PRODUCT MANUFACTURING SITE FOR EU IN ROVI, SPAIN

* EMA SAYS RECOMMENDATION BY AGENCY’S CHMP EXPECTED TO HAVE SIGNIFICANT IMPACT ON SUPPLY OF COMIRNATY, COVID-19 VACCINE, IN EUROPEAN UNION

* EMA SAYS DECISION REAFFIRMS PUURS FACILITY CAPABLE OF CONSISTENTLY PRODUCING HIGH-QUALITY VACCINES, ENABLES PFIZER/BIONTECH TO SCALE UP PRODUCTION PROCESS

* EMA - IS IN CONTINUOUS DIALOGUE WITH ALL MARKETING AUTHORISATION HOLDERS OF COVID-19 VACCINES AS THEY SEEK TO EXPAND PRODUCTION CAPACITY Source text: (bit.ly/3gA9vFc) Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up